Pixie Dust Technologies Inc Revenue Growth Rates (PXDT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Pixie Dust Technologies Inc   (NASDAQ: PXDT)
 

PXDT's Revenue Growth by Quarter and Year

Pixie Dust Technologies Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PXDT Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 6.30
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 6.30





PXDT Revenue fourth quarter 2024 Y/Y Growth Comment
Pixie Dust Technologies Inc achieved in the fourth quarter 2024, above Company average Revenue growth of 21.68% year on year, to $ 6.30 millions.

Looking into fourth quarter 2024 results within Medical Equipment & Supplies industry 51 other companies have achieved higher Revenue growth. While Pixie Dust Technologies Inc ' s Revenue rise of 21.68% ranks overall at the positon no. 689 in the fourth quarter 2024.


PXDT Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December 21.68 % - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   21.68 % - - -

Financial Statements
Pixie Dust Technologies Inc 's fourth quarter 2024 Revenue $ 6.30 millions PXDT's Income Statement
Pixie Dust Technologies Inc 's fourth quarter 2023 Revenue $ 5.18 millions Quarterly PXDT's Income Statement


PXDT Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   21.68 % - - -


Back to PXDT Growth rate Comparisons >> Back to PXDT Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #52
Healthcare Sector #183
Overall #689

Revenue Y/Y Growth Statistics
High Average Low
21.63 % 21.63 % 21.63 %
(Apr 30 2024)  
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #52
Healthcare Sector #183
Overall #689
Revenue Y/Y Growth Statistics
High Average Low
21.63 % 21.63 % 21.63 %
(Apr 30 2024)  

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Pixie Dust Technologies Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PXDT's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PXDT's IV. Quarter Q/Q Revenue Comment


Pixie Dust Technologies Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Apr 30 2024)		 12 Months Ending
 12 Months Ending
 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 6.30 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 21.63 % - - - -
Year on Year Revenue Growth Overall Ranking # 616 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 21.63 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 616 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With 21.63% annual Revenue growth, Pixie Dust Technologies Inc would report a record annual Revenue rise if the fiscal year would end on Apr 30 2024.

In the Healthcare sector 177 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 616.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 50
Healthcare Sector # 178
Overall # 616

Revenue TTM Y/Y Growth Statistics
High Average Low
21.63 %
 21.63 %
21.63 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 50
Sector # 178
S&P 500 # 616
Cumulative Revenue growth Comment
With 21.63% annual Revenue growth, Pixie Dust Technologies Inc would report a record annual Revenue rise if the fiscal year would end on Apr 30 2024.

In the Healthcare sector 177 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 616.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 50
Healthcare Sector # 178
Overall # 616

Revenue TTM Y/Y Growth Statistics
High Average Low
21.63 %
21.63 %
21.63 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 50
Sector # 178
S&P 500 # 616




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PXDT's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Apr 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Apr 30 2024
Abeona Therapeutics Inc 37.69%$ 37.685 millions
Lineage Cell Therapeutics Inc 37.36%$ 37.356 millions
Cvrx inc 36.83%$ 36.828 millions
23andme Holding Co36.17%$ 36.166 millions
Atrium Therapeutics Inc 35.57%$ 35.568 millions
Xeris Biopharma Holdings Inc 35.39%$ 35.389 millions
Alnylam Pharmaceuticals Inc 34.90%$ 34.897 millions
Corcept Therapeutics Inc34.33%$ 34.330 millions
Pro dex Inc 33.40%$ 33.405 millions
Therapeuticsmd Inc 32.87%$ 32.869 millions
Aurinia Pharmaceuticals Inc 32.76%$ 32.758 millions
Euda Health Holdings Limited32.37%$ 32.374 millions
Nexalin Technology Inc 32.27%$ 32.271 millions
Caredx Inc 32.04%$ 32.043 millions
Nuwellis Inc 31.92%$ 31.922 millions
Mannkind Corporation31.30%$ 31.304 millions
Lifevantage Corp31.05%$ 31.050 millions
Castle Biosciences Inc 30.54%$ 30.537 millions
Ethema Health Corporation 30.39%$ 30.392 millions
Nephros Inc 30.28%$ 30.277 millions
Guardant Health Inc 30.16%$ 30.157 millions
Amicus Therapeutics inc 30.09%$ 30.086 millions
Glaukos Corp29.85%$ 29.847 millions
Rapid Micro Biosystems Inc 29.68%$ 29.683 millions
Avita Medical Inc 29.67%$ 29.665 millions
Dynavax Technologies Corporation29.56%$ 29.561 millions
Halozyme Therapeutics Inc 29.55%$ 29.547 millions
International Stem Cell Corporation29.49%$ 29.487 millions
Ultragenyx Pharmaceutical Inc 29.42%$ 29.425 millions
Evolus Inc 29.42%$ 29.423 millions


About Pixie Dust Technologies Inc Revenue Growth Rates (PXDT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Pixie Dust Technologies Inc (CIK 1962845).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-24-071835
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Pixie Dust Technologies Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.